Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | ESRRG | P62508 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963472 | 0.93 | DRD2 (0.35) | MAPTDRD2LMNAL3MBTL1MAPK1 | |
| SCHEMBL4568624 | 0.93 | MAPT (0.36) | MAPTLMNAHSP90AA1HTTL3MBTL1 | |
| SCHEMBL2200006 | 0.88 | ACHE (0.35) | MAPTDRD2LMNAHTTALDH1A1 | |
| SCHEMBL1963473 | 0.88 | DRD2 (0.32) | DRD2 | |
| SCHEMBL13868743 | 0.86 | MAPT (0.35) | MAPTLMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL29453309 | 0.85 | STK10 (0.35) | MAPTLMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL1045266 | 0.85 | STK10 (0.35) | MAPTLMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL1046559 | 0.85 | MEN1 (0.32) | MAPTLMNAHTTALDH1A1 | |
| SCHEMBL29453311 | 0.85 | MEN1 (0.32) | MAPTLMNAHTTALDH1A1 | |
| SCHEMBL24620699 | 0.84 | ACHE (0.35) | MAPTHTTL3MBTL1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8709308-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20140034884-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-02-06 | — | — | US | disclosed |
| US-20140030529-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030529-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | MAPT 161/4885DRD2 844/4885ESRRG 4129/4885 |
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | MAPT 458/4885DRD2 1706/4885ESRRG 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.